银屑病合并念珠菌感染患者抗IL-17/12/23治疗的免疫学效应
研究比较了有皮肤和/或黏膜念珠菌感染史的银屑病患者在接受IL-17抑制剂或IL-12/23抑制剂治疗时的先天与适应性免疫应答,并与健康对照比较。结果显示IL-17i组CD4+Th1样和Th1 Th17样细胞百分比显著降低,白色念珠菌刺激后IL-6(IL-12/23i组)和IL-1β(IL-17i组)产生显著减少,而TNF-α和ROS释放与对照相似。IL-17i组对多种刺激的IFN-γ和IL-10产生及极化细胞因子刺激后的Th17细胞因子应答显著降低。
要点
- 有念珠菌感染史的银屑病患者接受IL-17i治疗时CD4+Th1样和Th1 Th17样细胞百分比显著降低。
- 白色念珠菌刺激后,IL-12/23i组IL-6产生显著降低,IL-17i组IL-1β产生显著降低。
- IL-17i组对多种刺激的IFN-γ和IL-10产生及极化细胞因子刺激后的Th17应答显著降低。
核心结论
- 这些先天和适应性免疫应答缺陷可削弱抗真菌宿主免疫应答,从而增加接受IL-17i或IL-12/23抑制剂治疗患者对念珠菌病的易感性。
研究设计与样本
- 研究纳入有皮肤和/或黏膜念珠菌感染史的银屑病患者,比较其在IL-17i或IL-12/23抑制剂治疗期间的先天和适应性免疫应答与健康对照的差异。
主要发现
- IL-17i组银屑病患者CD4+Th1样(CCR6‒CXCR3+CCR4‒)和Th1 Th17样(CD4+CCR6+CXCR3+CCR4‒)细胞百分比显著降低。
- 白色念珠菌刺激后,IL-12/23抑制剂组IL-6产生显著降低,IL-17i组IL-1β产生显著降低。
- 患者与对照之间TNF-α和ROS释放相似。
- IL-17i组对多种刺激7天后的IFN-γ和IL-10产生尤其降低。
- 极化细胞因子IL-1β和IL-23刺激后,IL-17i组Th17细胞因子应答显著降低。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Biologics that block the T helper (Th) 17 pathway are very effective in the treatment of psoriasis and other inflammatory diseases. However, IL-17 is also crucial for antifungal host defense, and clinical trial data suggest an increase in the incidence of Candida infections during IL-17 inhibitor (IL-17i) therapy. We investigated the innate and adaptive immune responses of patients with psoriasis with a history of skin and/or mucosal candidiasis during IL-17i or IL-12/23 inhibitor therapy, comparing those responses with those of healthy controls. Patients with psoriasis with IL-17i showed significantly lower CD4+Th1-like (CCR6‒CXCR3+CCR4‒) and Th1 Th17-like (CD4+CCR6+CXCR3+CCR4‒) cell percentages. Patient cells stimulated with Candida albicans produced significantly lower IL-6 in the IL-12/23 inhibitor group and IL-1β in the IL-17i group, whereas the release of TNF-α and ROS was similar between patients and controls. IFN-γ and IL-10 production in response to several stimuli after 7 days was particularly decreased in patients receiving IL-17i therapy. Finally, after stimulation with the polarizing cytokines IL-1β and IL-23, the Th17 cytokine response was significantly lower in the IL-17i patient group. These innate and adaptive immune response defects can diminish antifungal host immune response and thereby increase susceptibility to candidiasis in patients treated with IL-17i or IL-12/23 inhibitor.
引用
- Bruno M, Davidson L, Koenen HJPM, et al. Immunological Effects of Anti‒IL-17/12/23 Therapy in Patients with Psoriasis Complicated by Candida Infections. J Invest Dermatol. 2022. PMID: 35662644. doi:10.1016/j.jid.2022.05.1083
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。